Communiqués Orgenesis Inc.

Actions

ORGS

US68619K3032

Equipement, fournitures et distribution médicale

Marché Fermé - OTC Markets Autres places de cotation 18:05:22 15/07/2026			Varia. 5j.	Varia. 1 janv.
0,0190 ^USD	-5,00%		-95,25%	-87,33%

26/03	Orgenesis Inc. publie ses résultats annuels pour l'exercice clos le 31 décembre 2024	CI
26/03	Orgenesis Inc. : l'auditeur émet des doutes sur la continuité de l'exploitation	CI

Communiqués

26/03	Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
13/11/24	Orgenesis Provides Third Quarter 2024 Business Update	AQ
21/10/24	Orgenesis Commences Trading on OTCQX® Best Market	AQ
23/09/24	Orgenesis Announces Reverse Stock Split	AQ
29/08/24	Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia	AQ
14/08/24	Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally	AQ
08/08/24	Orgenesis Provides Second Quarter 2024 Business Update	AQ
21/05/24	Orgenesis Provides Business Update for the First Quarter of 2024	AQ
15/04/24	Orgenesis Provides Year End Business Update	AQ
15/04/24	Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
10/04/24	Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	AQ
18/03/24	Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	AQ
13/03/24	Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	AQ
04/03/24	Orgenesis Inc. Announces $2.3 Million Private Placement	AQ
29/02/24	Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	AQ
31/01/24	Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	AQ
14/11/23	Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	AQ
13/11/23	Orgenesis Provides Business Update for the Third Quarter of 2023	AQ
08/11/23	Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering	AQ
02/11/23	Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding	AQ
31/10/23	Orgenesis Announces Withdrawal of Proposed Public Offering	AQ
30/10/23	Orgenesis Announces Proposed Underwritten Public Offering	AQ
21/09/23	CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States	AQ
06/09/23	Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support	AQ
11/08/23	Orgenesis Provides Business Update for Second Quarter of 2023	AQ